Sanofi Ventures — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
AdvanCell develops radioisotope-based therapies, using Th-228 sourced through the U.S.
BiotechHealthtechMedical DevicesCambridge, US
Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)Wing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)Jamil Beg(Director)
Board seatChristopher Gagliardi· per SEC Form D
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
Zach Scheiner(Director)William Daley Bonificio(Executive Officer, Promoter)Megan Krench(Director)Stephen Basil Thomas(Executive Officer, Promoter)Dmitrij Hristodorov(Director)Naveen Manu Daryani(Executive Officer, Director, Promoter)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.